Cryosite Ltd (CTE) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.361x

Based on the latest financial reports, Cryosite Ltd (CTE) has a cash flow conversion efficiency ratio of 0.361x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$1.30 Million ≈ $921.96K USD) by net assets (AU$3.61 Million ≈ $2.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cryosite Ltd (CTE) defensive interval to measure how many days the company can operate on defensive assets alone.

Cryosite Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)

This chart illustrates how Cryosite Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cryosite Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cryosite Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Yukselen Celik As
IS:YKSLN
0.232x
Smr Utama Tbk
JK:SMRU
0.656x
Bluerock Homes Trust Inc.
NYSE MKT:BHM
0.021x
Yesil Yapi Endustrisi AS
IS:YYAPI
0.001x
Hi Sharp Electronics Co Ltd
TWO:3128
-0.015x
HYUNDAI BIOLAND Co.Ltd
KQ:052260
0.102x
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
0.001x
Excelsior Biopharma
TWO:6496
-0.028x

Annual Cash Flow Conversion Efficiency for Cryosite Ltd (2001–2025)

The table below shows the annual cash flow conversion efficiency of Cryosite Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see CTE market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$2.39 Million
≈ $1.69 Million
AU$2.06 Million
≈ $1.46 Million
0.864x -54.36%
2024-06-30 AU$1.45 Million
≈ $1.03 Million
AU$2.74 Million
≈ $1.94 Million
1.893x +274.03%
2023-06-30 AU$2.78 Million
≈ $1.97 Million
AU$1.41 Million
≈ $996.25K
0.506x -62.25%
2022-06-30 AU$1.86 Million
≈ $1.32 Million
AU$2.49 Million
≈ $1.77 Million
1.341x +130.27%
2021-06-30 AU$819.23K
≈ $579.65K
AU$476.96K
≈ $337.48K
0.582x -93.10%
2020-06-30 AU$154.88K
≈ $109.58K
AU$1.31 Million
≈ $924.35K
8.435x +2135.42%
2019-06-30 AU$-1.72 Million
≈ $-1.21 Million
AU$-647.54K
≈ $-458.17K
0.377x +379.99%
2018-06-30 AU$1.94 Million
≈ $1.38 Million
AU$-261.91K
≈ $-185.32K
-0.135x -126.08%
2017-06-30 AU$3.15 Million
≈ $2.23 Million
AU$1.63 Million
≈ $1.15 Million
0.517x +267.77%
2016-06-30 AU$3.38 Million
≈ $2.39 Million
AU$474.61K
≈ $335.82K
0.140x -64.86%
2015-06-30 AU$3.54 Million
≈ $2.51 Million
AU$1.42 Million
≈ $1.00 Million
0.400x +54.74%
2014-06-30 AU$6.14 Million
≈ $4.34 Million
AU$1.58 Million
≈ $1.12 Million
0.258x -16.57%
2013-06-30 AU$6.26 Million
≈ $4.43 Million
AU$1.94 Million
≈ $1.37 Million
0.310x -9.74%
2012-06-30 AU$5.48 Million
≈ $3.88 Million
AU$1.88 Million
≈ $1.33 Million
0.343x +13.39%
2011-06-30 AU$4.69 Million
≈ $3.32 Million
AU$1.42 Million
≈ $1.00 Million
0.303x +34.76%
2010-06-30 AU$4.35 Million
≈ $3.08 Million
AU$977.66K
≈ $691.75K
0.225x +37.27%
2009-06-30 AU$4.34 Million
≈ $3.07 Million
AU$709.86K
≈ $502.27K
0.164x -20.44%
2008-06-30 AU$4.32 Million
≈ $3.06 Million
AU$888.27K
≈ $628.51K
0.206x +10.08%
2007-06-30 AU$3.74 Million
≈ $2.64 Million
AU$697.65K
≈ $493.63K
0.187x +358.76%
2006-06-30 AU$2.81 Million
≈ $1.99 Million
AU$-203.02K
≈ $-143.65K
-0.072x +10.55%
2005-06-30 AU$2.48 Million
≈ $1.75 Million
AU$-199.90K
≈ $-141.44K
-0.081x +66.81%
2004-06-30 AU$3.04 Million
≈ $2.15 Million
AU$-738.72K
≈ $-522.69K
-0.243x +20.88%
2002-06-30 AU$3.89 Million
≈ $2.75 Million
AU$-1.20 Million
≈ $-845.61K
-0.307x -27.31%
2001-06-30 AU$3.87 Million
≈ $2.74 Million
AU$-933.52K
≈ $-660.52K
-0.241x --

About Cryosite Ltd

AU:CTE Australia Diagnostics & Research
Market Cap
$36.61 Million
AU$51.74 Million AUD
Market Cap Rank
#23076 Global
#858 in Australia
Share Price
AU$1.06
Change (1 day)
+0.00%
52-Week Range
AU$0.66 - AU$1.30
All Time High
AU$1.30
About

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more